Search
  • DLRG

Cell-free biotech could drive COVID-19 therapeutics

Updated: May 10

Platform could produce new antiviral drugs more than 10 times faster


A biomanufacturing company spun out of Cornell research is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert F. Smith School of Chemical and Biomolecular Engineering, and his longtime collaborator, Michael Jewett, a professor of chemical and biological engineering at Northwestern University.


To learn more, see the stories:

https://news.cornell.edu/stories/2020/04/cell-free-biotech-could-drive-covid-19-therapeutics

https://news.northwestern.edu/stories/2020/04/cell-free-biotechnology-could-help-accelerate-covid-19-therapeutics/

35 views

Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey

© 2018 by DLRG. Proudly created with Wix.com